Ovasave, founded in 2023 and based in Abu Dhabi, provides a digital-first platform for women’s fertility and hormonal health. Its offerings include at-home hormone testing, virtual consultations, tailored supplement plans, and coordinated access to leading fertility clinics for egg freezing. The startup also operates a growing corporate benefits program and runs public-education initiatives, including a 2024 “Fertility Your Way” campaign with Merck KGaA that provided free AMH screenings to over 500 women. Ovasave plans to launch in Saudi Arabia this summer and pursue wider MENA expansion over the next three years. The company will use recent funding to accelerate corporate partnerships and to roll out the next phase of its mobile app—adding menstrual cycle tracking, symptom monitoring, integrated care access, and AI-powered treatment plans—and to expand support for perimenopause and menopause. The team notes regulatory fragmentation and cultural nuances across MENA as operational challenges while emphasizing a mission to shift care from reactive treatment to proactive support.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2025